The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NovoCure makes Optune, a battery-powered device that brain cancer patients wear to prevent cancer cells from multiplying. NovoCure has grown quickly in recent years, but sales of its devices appear to ...
Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results